Clinical trials: Solid Tumors, completed
Metastatic Non-Small Cell Lung Carcinoma, Solid Tumor, Adult
Perfusion-Induced Hyperthermia for Metastatic Carcinoma
The purpose of this study is to gather information on how safe the hyperthermia treatment delivered via the Exatherm-TBH (the device that will heat your blood and deliver it back to you), added to the best supportive care is to…
- Trial name
- NCT02409108
- Testing
- Exatherm-TBH system
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Jonathan Kiev
Patients With Any Advanced Solid Tumors
Trial Of Pembrolizumab And Nintedanib
Both anti-angiogenesis and anti PD1 immunotherapy have shown beneficial efficacy in solid tumors and in particular in NSCLC. Therefore it is of interest to investigate whether the combination of these two approaches is tolerable.
- Trial name
- PEMBIB (NCT02856425)
- Testing
- Nintedanib, Pembrolizumab
- Where
- 5 sites in France
- Volunteers
- 196 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Neoplasms
Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)
This is a safety and pharmacokinetics study of favezelimab as monotherapy and in combination with pembrolizumab AND favezelimab/pembrolizumab as monotherapy in adults with metastatic solid tumors for which there is no available…
- Trial name
- NCT02720068
- Testing
- Favezelimab, Pembrolizumab, Oxaliplatin
- Volunteers
- 481 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
This Phase Ib/II study is an open label, multicenter study. The study is divided in two parts: Phase I: an open-label, dose escalation study of F16IL2 in combination with paclitaxel for patients with solid tumours, bladder…
- Conditions
- Solid Tumor, Breast Cancer, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT01134250
- Testing
- F16IL2 in combination with paclitaxel
- Where
- 5 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Philogen S.p.A.
Advanced Solid Tumors, Metastatic Solid Tumors
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
A Phase I dose escalation study to determine the safety, tolerability, pharmacodynamics and preliminary anti-tumor activity of BMS-754807 in combination with chemotherapy drugs, paclitaxel and carboplatin, in patients with…
- Trial name
- NCT00793897
- Testing
- BMS-754807, Paclitaxel, Carboplatin
- Where
- 5 sites in Australia, Canada and 1 more
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
The purpose of this study is to determine safety and effectiveness of experimental medication BMS-986205 in combination with Nivolumab in patients with cancers that are advanced or have spread.
- Trial name
- NCT03792750
- Testing
- BMS-986205, Nivolumab
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Bristol-Myers Squibb
Advanced Cancer
AST-021p Study in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and optimal Immunogenic dose of therapeutic cancer vaccine (AST-021p) in patients With advanced solid tumors A phase 1 study
- Trial name
- NCT04864418
- Testing
- AST-021p
- Where
- 3 sites in South Korea
- Volunteers
- 22 people
- Sponsor
- Aston Sci. Inc.
Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm
Integrative Palliative Care/Psycho-Oncology Telehealth Intervention in Patients With Advanced Cancer
This trial investigates whether a joint and integrative approach to cancer care using palliative care and psycho-oncology is possible, and if it's beneficial to patients with cancer that has spread to other places on the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT04697524
- Testing
- Support Group Therapy, Symptom Management Service (SMS) Consultation, Quality of Life (QOL) Questionnaires
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Unspecified Adult Solid Tumor, Protocol Specific
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of SB939 in treating patients with locally…
- Trial name
- NCT00504296
- Testing
- HDAC inhibitor SB939, immunoenzyme technique, immunohistochemistry staining method
- Where
- 2 sites in Canada
- Volunteers
- 39 people
- Sponsor
- NCIC Clinical Trials Group
Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
This is a prospective, single arm, phase Ib/IIa study. Up to 25 patients will be enrolled into the study (Part A: 2-18; Part B: 7-19).
- Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation, Locally Advanced Solid Tumor, Metastatic Cancer, Adenocarcinoma of Lung
- Trial name
- AUTOMAN (NCT04770688)
- Testing
- Osimertinib, Anlotinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Chest Hospital
Advanced Solid Tumor, Lymphoma
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas
DS-3078a will be evaluated as a single agent in subjects with advanced solid tumor malignancies or lymphomas refractory to standard treatment or for which no standard treatment is available.
- Trial name
- NCT01588678
- Testing
- DS-3078a
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Daiichi Sankyo
Cancer, Neoplasm Metastasis
Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
This study is being performed to evaluate the safety and tolerability of the TRC105 monoclonal antibody.
- Trial name
- NCT00582985
- Testing
- TRC105 chimeric anti-CD105 antibody
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Lymphomas, Tumors
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
Determine toxicity and maximum tolerated dose of escalating daily protracted irinotecan, with weekly vincristine, temozolomide and vantin; to evaluate the feasibility of repetitive cycles of this chemotherapy and to estimate the…
- Trial name
- NCT00222443
- Testing
- Irinotecan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Oklahoma
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Phase I trial to study the effectiveness of combining alvocidib, irinotecan hydrochloride, and cisplatin in treating patients who have advanced solid tumors.
- Trial name
- NCT00046917
- Testing
- alvocidib, irinotecan hydrochloride, cisplatin
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Hepatocellular Carcinoma
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus expressing interferon beta in treating patients with liver cancer or solid tumors with lesions that have spread to other parts of…
- Trial name
- NCT01628640
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
This phase I trial is studying the side effects and best dose of R-(-)-gossypol acetic acid when given together with cisplatin and etoposide in treating patients with advanced solid tumors or extensive stage small cell lung…
- Trial name
- NCT00544596
- Testing
- R-(-)-gossypol acetic acid, cisplatin, etoposide
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumours
Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours
The purpose of this study is to assess the effect of food on the pharmacokinetics (PK) of a single dose of AZD1775 (printed capsules) in patients with advanced solid tumours.
- Trial name
- NCT03315091
- Testing
- Treatment A - AZD1775 administered under fasted conditions, Treatment B - AZD1775 administered under fed conditions.
- Where
- 7 sites in France, Netherlands and 1 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Neoplasms, Cancer
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors
This is a non-randomized, multi-dose, first-in-human, multicenter, two arm (Arm A: VGX-100 alone; Arm B: VGX-100 co-administered with bevacizumab), open label, dose escalation study in subjects with advanced or metastatic solid…
- Trial name
- NCT01514123
- Testing
- VGX-100, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- Circadian Technologies Ltd.
Solid Tumor
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
This is an open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study in patients with advanced solid tumors.
- Trial name
- NCT01170897
- Testing
- PEGPH20
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Halozyme Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.